Nitric oxide (NO) became a sudden celebrity in the early 1990s, as scientists recognized that the gas long known as a component of cigarette smoke and smog is also a vital chemical messenger within the body, but no one has yet been able to channel the academic understanding of NO into successful new medicines. Novan Inc. believes it can succeed where others have failed – the start-up aims first to create a topical treatment for acne, and then to pursue other first-in-class treatments in the field of dermatology.
Novan Inc.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
